针对产金属 β- 内酰胺酶（MBL）铜绿假单胞菌感染治疗难题，研究用头孢吡肟 / 齐德巴坦治疗患者获临床和微生物学治愈 ...

Exblifep是一种静脉注射用的固定剂量抗生素组合，包括enmetazobactam ——一种新型广谱β-内酰胺酶抑制剂，以及第四代头孢菌素cefepime，这种组合显著 ...

Cefepime–taniborbactam is an investigational β-lactam and β-lactamase inhibitor combination with activity against Enterobacterales species and P. aeruginosa expressing serine and metallo-β ...

Two oral presentations will showcase cefepime-taniborbactam and highlight the safety and efficacy results from the recently completed pivotal Phase 3 complicated urinary tract infection clinical ...

Review the side-effects of Cefepime as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

Credit: Getty Images. A PDUFA target date of February 22, 2024 has been set for this application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...

For complicated urinary tract infection, the efficacy and safety of the investigational cefepime–taniborbactam combination, in comparison with standard treatment with meropenem, are unknown.

No cases of neutropenia were reported for the 121 courses of antimicrobials other than cefepime. Among the 13 courses of cefepime therapy, 8 resulted in neutropenia after an average of 25 days of ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for cefepime-taniborbactam for the treatment of adults with complicated urinary tract ...

Further information Decision makers have concluded that this technology will not progress as a potential technology appraisal or a highly specialised technology. Traditional approaches to ...